Summary
The plasma levels, organ distribution, and in vivo antitumor activity of free and liposomal doxorubicin injected into the hepatic artery of rats bearing W256 liver tumors were studied. The administration of liposomal doxorubicin resulted in liver-tumor and liver-parenchyma doxorubicin areas under the curve (AUCs) that were 4.7-and 3.8-fold, respectively, those obtained after the administration of free doxorubicin. Spleen and plasma AUCs were also increased by 2.8 and 2.5 times, respectively, following administration of the liposomal form. In contrast, liposomal doxorubicin did not affect heart AUCs; peak doxorubicin levels in heart tissue were three times lower in animals treated with liposomal doxorubicin. Following treatment with the liposomal form, the cumulative urinary excretion of doxorubicin at 8 h was 38 times lower. In good correlation with these findings, liposomal doxorubicin (2.35 mg/kg on day 7) was more effective than free doxorubicin against liver W256 tumors as measured by tumor-growth inhibition at 5 days after treatment (16% for liposomal doxorubicin versus −53.7% for free doxorubicin,P<0.05) and increased life span (ILS; 108% for liposomal doxorubicin versus 27% for free doxorubicin,P<0.05). These results demonstrate that as compared with free doxorubicin, the administration of liposomal doxorubicin into the hepatic artery results in higher drug levels in the liver tumor and enhanced antitumor activity while maintaining the cardioprotective effect of the liposome carrier as suggested by the decreased peak drug levels measured in the heart tissue.
Similar content being viewed by others
References
Balazsovitz JAE, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE (1989) Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23:81–86
Bartlett GR (1959) Phosphorus assay in column chromatography. J Biol Chem 234:466–470
Bern MM, McDermott W, Cady B, Oberfield RA, Trey C, Clouse ME, Tullis JL, Parker LM (1978) Intraarterial hepatic infusion and intravenous Adriamycin for treatment of hepatocellular carcinoma. Cancer 42:399–405
Breedis C, Young G (1954) The blood supply of neoplasma in the liver. Am J Pathol 30:227–232
Carlsson G, Gustavsson B, Hafstrom L (1989) Effect on liver tumor growth in rats of allopurinol and 5-fluorouracil in combination with hepatic artery ligation. Cancer Chemother Pharmacol 23:169–172
Doci R, Bignanmi P, Bozzetti F, Bonfanti, G, Audisio R, Colombo M, Gennari L (1988) Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 61:1983–1987
Eksborg S, Cedermark BJ, Strandler HS (1987) Intrahepatic and intravenous administration of Adriamycin. A comparative pharmacokinetic study in patients with malignant liver tumors. Med Oncol Tumor Pharmacother 2:47–54
Gabizon A, Goren D, Fuks Z, Meshorer A, Barenholz Y (1985) Superior therapeutic activity of liposome-associated Adriamycin in murine metastatic tumor model. Br J Cancer 51:681–687
Gabizon A, Meshorer A, Barenholz Y (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77: 459–469
Gregoriadis G, Neerunjun DE, Hunt R (1977) Fate of a liposome-associated agent injected into normal and tumor-bearing rodents; attempts to improve localization in tumor tissues. Life Sci 21: 357–369
Hag IAEL, Teder H, Roos G, Christensson PI, Stenram U (1990) Enhanced effect of Adriamycin on a rat liver adenocarcinoma after hepatic artery injection with degradable starch microspheres. Select Cancer Ther 6:23–34
Healy JE (1965) Vascular patterns in human metastatic liver tumor. Surg Gynecol Obstet 120:1187–1193
Herman EH, Rahman A, Ferrans V, Vick JA, Schein PS (1983) Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 43:5427–5432
Inoue H, Kobayashi H, Itoh Y, Shinohara S (1989) Treatment of liver metastases by arterial injection of Adriamycin/mitomycin C lipiodol suspension. Acta Radiol 30:603–608
Kemeny N, Schneider A (1989) Regional treatment of hepatic metastases and hepatocellular carcinoma. Curr Probl Cancer 13:197–283
Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma, a randomized trial. Ann Intern Med 107:459–467
Khokhar AR, Wright K, Siddik ZH, Perez-Soler R (1988) Organ distribution and tumor uptake of liposome-entrappedcis-bis-neodecanoato-trans-R, R-1,2-diamino-cyclohexane platinum(II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol 22:223–227
Kinami Y, Miyazaki I (1978) The superselective and the selective one shot methods for treating inoperable cancer of the liver. Cancer 41:1720–1727
Lien WM, Ackerman NB (1970) The blood supply of experimental liver metastases. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 68:334–340
Mayhew E, Papahandjopoulos D (1983) Therapeutic application of liposomes. In: Ostro MJ (ed) Liposomes. Marcel Dekker, New York, pp 289–341
Mayhew E, Rustum Y, Vail WJ (1983) Inhibition of liver metastases of M-5076 tumor by liposome-entrapped Adriamycin. Cancer Drug Deliv 1:43–49
Mayhew E, Goldrosen MH, Vaage J, Rustum YM (1987) Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst 78:707–713
Nakamura H, Hashimoto T, Oi H, Sawada S (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–789
Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit G (1988) Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver. Cancer 61: 1884–1888
Ridge JA, Collin C, Bading JR, Hancock C, Conti PS, Daly JM, Raaf JH (1988) Increased Adriamycin levels in hepatic implants of rabbit VX2 carcinoma from regional infusion. Cancer Res 48: 4584–4587
Sasaki Y, Imaoka S, Hasegawa Y, Nagano S, Ishikawa O, Ohigashi H, Taniguchi K, Koyama H, Iwanaga T, Terasawa T (1985) Distribution of arterial blood flow in human hepatic cancer during chemotherapy-examination by short-lived81mKr. Surgery 97: 409–413
Sterchi JM (1985) Hepatic artery infusion for metastatic neoplastic disease. Surg Gynecol Obstet 169:477–489
Szoka F Jr, Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75:4194–4199
Wondergem J, Stephen LC, Strebel FR, Baba H, Ohno S, Siddik ZH, Newman RA, Bull JMC (1991) Effect of Adriamycin combined with whole body hyperthermia on tumor and normal tissues. Cancer Res 51:3559–3567
Zou Y, Ueno M, Yamagishi M, Yamashita I, Horikoshi I, Tazawa K, Gu X (1990) Targeting behavior of hepatic artery-injected temperature-sensitive liposomal Adriamycin on tumor-bearing rats. Select Cancer Ther 6:119–127
Zou Y, Horikoshi I, Ueno M, Gu X (1992) The quantitative analysis of Adriamycin and liposomal Adriamycin injected into the hepatic artery in vivo. J SYC Pharm 9:6–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zou, Y., Horikoshi, I., Kasagi, T. et al. Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery. Cancer Chemother. Pharmacol. 31, 313–318 (1993). https://doi.org/10.1007/BF00685677
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685677